Apigenin causes necroptosis by inducing ROS accumulation, mitochondrial dysfunction, and ATP depletion in malignant mesothelioma cells

Yoon-Jin Lee¹, Kwan-Sik Park¹, Hae-Seon Nam², Moon-Kyun Cho², and Sang-Han Lee¹*

¹Department of Biochemistry, Soonchunhyang University College of Medicine; ²Division of Molecular Cancer Research, Soonchunhyang Medical Research Institute, Soonchunhyang University, Cheonan 31151, Korea

ABSTRACT Apigenin, a naturally occurring flavonoid, is known to exhibit significant anticancer activity. This study was designed to determine the effects of apigenin on two malignant mesothelioma cell lines, MSTO-211H and H2452, and to explore the underlying mechanism(s). Apigenin significantly inhibited cell viability with a concomitant increase in intracellular reactive oxygen species (ROS) and caused the loss of mitochondrial membrane potential (ΔΨm), and ATP depletion, resulting in apoptosis and necroptosis in monolayer cell culture. Apigenin upregulated DNA damage response proteins, including the DNA double strand break marker phospho (p)-histone H2A.X. and caused a transition delay at the G2/M phase of cell cycle. Western blot analysis showed that apigenin treatment upregulated protein levels of cleaved caspase-3, cleaved PARP, p-MLKL, and p-RIP3 along with an increased Bax/Bcl-2 ratio. ATP supplementation restored cell viability and levels of DNA damage-, apoptosis- and necroptosis-related proteins that apigenin caused. In addition, N-acetylcysteine reduced ROS production and improved ΔΨm loss and cell death that were caused by apigenin. In a 3D spheroid culture model, ROS-dependent necroptosis was found to be a mechanism involved in the anti-cancer activity of apigenin against malignant mesothelioma cells. Taken together, our findings suggest that apigenin can induce ROS-dependent necroptotic cell death due to ATP depletion through mitochondrial dysfunction. This study provides us a possible mechanism underlying why apigenin could be used as a therapeutic candidate for treating malignant mesothelioma.

INTRODUCTION DNA damage, including base substitution, DNA cross-links, single- or double-strand break (DSB), are phenomena that occur as a result of environmental assaults such as chemotherapy, radiation, polycyclic hydrocarbons, and ultraviolet light. Activating cell cycle checkpoints through the DNA damage response (DDR) occurs in response to DNA damage in mammalian cells [1]. During this process, a temporary arrest or delay in transition occurs at certain stages of the cell cycle (G0/G1 or G2/M phase), allowing cells to correct possible defects in the genome [2]. This reaction eventually restores the continuity of DNA double strands and helps cells avoid propagation of genetic lesions to daughter cells. However, it triggers cell death pathway if DNA lesions are irreparable.

Mitochondria are important for the control of cell survival and cell death. The ability of mitochondria to modulate cell death is generally related to their roles in reactive oxygen species (ROS) production and ATP generation [3]. Mitochondrial dysfunction is usually accompanied by loss of transmembrane potential and

*Correspondence Sang-Han Lee E-mail: m1037624@sch.ac.kr

Key Words
Apigenin
Apoptosis
Mesothelioma
Necroptosis
Reactive oxygen species

Original Article
accumulation of ROS [4]. The mitochondrial membrane gradient’ collapse increases electron leakage in the electron transport chain (ETC) and potentially leads to excessive ROS levels. When ROS concentration reaches a certain threshold level and overwhelms the antioxidant function, this causes damage to macromolecules and organelles, eventually leading to cell death [5]. However, moderate ROS levels are important for redox-dependent signaling to maintain physiological functions, including cell differentiation, proliferation, and survival.

Malignant mesothelioma (MM) is a highly lethal tumor arising from the mesothelium of serous cavities of the lung, pleura or peritoneum. Although combination with pemetrexed and cisplatin is currently the first-line treatment for patients with MM [6], this therapeutic regimen has shown poor outcome due to drug resistance. Impaired capacity to undergo apoptosis is known to be one of the leading causes of treatment failures and relapses [7]. Deregulation of many molecules that regulate apoptosis, such as intrinsic pathway (bcl-2 family, PI3K-Akt and Wnt signalings), or extrinsic pathway (TRAIL, NF-kB and ERK1/2 signalings) has been shown in MM tumorigenesis [8]. Therefore, the development of therapeutic approaches that restore apoptosis or trigger non-apoptotic cell death can overcome treatment resistance for MM and provide an opportunity to address the unmet need for this deadly disease.

Apoptosis is considered a well-defined form of programmed cell death (PCD), whereas necroptosis, one of PCD pathways, still has much to be proven. Necroptosis is initiated by activation of receptor-interacting protein kinase (RIPK) 1, which then binds to RIPK3 and activates it to form a necrosome. These events will ultimately trigger necroptosis by activating mixed lineage kinase domain like protein (MLKL) [9]. Several chemotherapeutic drugs, including etoposide, taxol, 5-fluorouracil, and camptothecin, as well as several natural products such as shikonin, β-lapachone, and eupomatenoid-5 can induce necroptosis in various cancer cells [10,11]. Evidence has shown that necroptosis can function as a protective mechanism to kill cancer cells that lack the mechanism(s) of DNA damage-induced apoptosis, suggesting that targeting necroptosis is an attractive anticancer strategy for apoptosis-resistant tumors [11].

Among the many bioactive substances in nature, apigenin (4’,5,7-trihydroxyflavone), a flavone abundant in parsley, orange, celery, chamomile, and onion, because of its chemopreventive and chemotherapeutic effects on various types of cancers, including breast, thyroid, prostate, liver, and breast cancer cells [12], it has been reported as an anticancer agent. Apigenin can inhibit cancer cell proliferation by inducing apoptosis, modulating the cell cycle, inhibiting invasion and metastasis, and stimulating the immune responses [12-14]. During those processes, apigenin regulates many signaling pathways, including PI3-kinase/Akt, p38/MAPK, JNK/STAT, and NF-κB. Although anti-cancer effects of apigenin have been proven in several studies, little is known about its effect on MM.

Two-dimensional monolayer cultures of cancer cells do not adequately reproduce the natural structure of tumors in vivo, interactions of cells with cells or microenvironments in tumor mass [15]. In addition, metabolic stresses such as hypoxia and acidic pH found in tumor microenvironments are considered as main causes of tumor aggressiveness and chemoresistance [16]. Therefore, establishing experimental conditions considering effects of extracellular acidic pH in a tumor microenvironment might be useful for the development of more effective treatment candidates. To compensate for the shortcomings of 2D cell culture and to mimic the in vivo environment, we analyzed effects of apigenin after adapting cells to an acidic environment through prolonged preconditioning in a culture medium containing lactic acid and confirmed the results obtained in 2D monolayer cell culture with a 3D spheroid culture model.

The study aims to verify the efficacy of apigenin as a candidate anticancer agent for MM and underlying mechanism(s) involved in anti-cancer effect. We present here that apigenin can cause cell death by targeting necroptosis through ROS-mediated mitochondrial dysfunction and DNA damage as a novel mechanism.

**METHODS**

**Reagents and cell culture**

Apigenin (catalog no. 149930, ≥ 95.0% purity), lactic acid, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), cisplatin (catalog no. P4394), fluorescein diacetate (FDA), propidium iodide (PI), casein blocking buffer, dimethylsulfoxide (DMSO), 2',7'-dichlorodihydrofluorescein diacetate (DCFDA), rhodamine 123, and Tween-20 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies for MLKL (catalog no. 14993), p-MLKL (catalog no. 91689), RIP3 (catalog no. 13526), p-RIP3 (catalog no. 93654), p-ataxia-telangiectasia mutated (Ser1391 (ATM Ser1391), catalog no. 5883), p-ATM-related (Ser28 (ATR Ser28), catalog no. 2853), p-histone H2A.X (Ser139) (catalog no. 9718), Bax (catalog no. 5023), Bcl-2 (catalog no. 2820), caspase-3 (catalog no. 9665), cleaved caspase-3 (catalog no. 9664), PARP (catalog no. 9542), and cleaved PARP (catalog no. 9541) were purchased from Cell Signaling Technology, Inc. (Danvers, CO, USA). Goat anti-rabbit IgG-horseradish-peroxidase (HRP), catalog no. sc-2004, mouse anti-goat IgG-HRP (catalog no. sc-2354), and goat anti-mouse IgG-HRP (catalog no. sc-2005) were purchased from Santa-Cruz Biotechnology (Dallas, TX, USA). Human mesothelioma cell lines MSTO-211H and H-2452 and human mesothelial cell line, MeT-5A, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human mesothelioma cell lines MSTO-211H and H-2452 and human mesothelial cell line MeT-5A were obtained from the American Type Culture Collection (ATCC). MSTO-211H and H-2452 cells were preadapted to acidic medium by continuous exposure to lactic acid (3.8 μM) via serial
were incubated with primary antibodies at 4°C overnight. After 1× casein blocking buffer (Sigma-Aldrich), PVDF membranes (GE Health Science, Munich, Germany) were placed in 1× PBS, Muse Cell Cycle reagent (Merck Millipore, Burlington, MA, USA) was added to cells. DNA distribution from 10,000 cells was analyzed with MACSQuant Analyzer and MACSQuantify software version 2.5 (Miltenyi Biotec GmbH; GmbH, Bergisch, Germany). Cell viability was determined by comparing absorbance values to those of vehicle-treated cells (100%).

**Cell viability assay**

Cells were seeded into 96-well plates at density of 5 × 10^4 cells in 100 µl complete medium per each well. The next day, cells were treated with vehicle (DMSO) or apigenin at various concentrations shown in the Figure legends (Figs. 1–3, and 5). After adding MTT reagent to each well, the plate was incubated at 37°C for 4 h. Absorbance values were measured in a wavelength of 540 nm using a GloMax-Multi Microplate Multimode Reader (Promega Corporation, Durham, NC, USA). Cell viability was determined by comparing absorbance values to those of vehicle-treated cells (100%).

**Cell cycle analysis**

Cell cycle was analyzed by quantifying the DNA content in cells stained with PI. Briefly, cells were harvested, fixed with 70% ethanol, and left at −20°C overnight. After washing and resuspended in 1× PBS, Muse Cell Cycle reagent (Merck Millipore, Burlington, MA, USA) was added to cells. DNA distribution from 10,000 cells was analyzed with MACSQuant Analyzer and MACSQuantify software version 2.5 (Miltenyi Biotec GmbH; GmbH, Bergisch, Germany).

**Annexin V-PE binding assay**

Apoptotic and necrotic cell distribution were determined by using Muse Annexin V & Dead Cell Assay kit (Merck KGaA). Briefly, cells were harvested after treatment with apigenin and labeled with annexin V-phycocerythin and 7-amino-actinomycin D at room temperature for 20 min in the dark. Stained cells (5 × 10^5) were then analyzed with Muse Cell Analyzer (Merck KGaA).

**Western blot analysis**

Cells were washed and lysed with 1× RIPA buffer. Protein quantitation was then performed by using a BCA protein assay kit (Thermo Fisher, Waltham, MA, USA). Proteins (40 µg) of each cell lysate were loaded onto 4%–12% NuPAGE gel (Invitrogen, Carlsbad, CA, USA) for electrophoresis and electro-transferred to a polyvinylidene difluoride (PVDF) membranes (GE Healthcare Life Science, Munich, Germany). After blocking for 2 h with 1× casein blocking buffer (Sigma-Aldrich), PVDF membranes were incubated with primary antibodies at 4°C overnight. After washing the membrane with 1× PBS containing Tween-20, it was incubated with HRP-conjugated secondary antibodies at room temperature for 2 h. Reactive proteins were visualized on an X-ray film by using enhanced chemiluminescence detection kit (Cyagen, Bologna, Italy). Membranes were re-probed with antibodies to anti-β-actin (Sigma-Aldrich) which served as a loading control.

**Measurement of ROS and mitochondrial membrane potential**

Cells were seeded into 6-well culture plates at density of 10^5 cells in 2 ml complete medium/well overnight. The next day, cells were then treated with apigenin in complete DMEM for the indicate time shown in the Figure legends (Figs. 3, 4). Cells were harvested by centrifugation, and then stained with 10 µM DCF-DA and 30 nM rhodamine 123 to measure the levels of ROS and mitochondrial membrane potential (ΔΨm), respectively, in the dark at 37°C for 30 min. After washing cells with 1× PBS, the average fluorescence intensity of 10,000 cells was measured by using the MACSQuant Analyzer with MACSQuantify software version 2.5.

**Measurement of intracellular ATP level**

Intracellular ATP levels were measured by using the CellTiter-Glo Luminescent Cell Viability Assay (Promega Corporation). Briefly, cells were treated with apigenin for different time periods, after which CellTiter-Glo reagent (100 µl) was added to each well. Luminescence values produced by the luciferase-catalyzed luciferin was measured using a GloMax-Multi Microplate Multimode Reader. These values were compared to those of vehicle-treated control cells (100%) for each time point.

**Spheroid culture and viability assay**

Cells were seeded into ultra-low attachment 96-well plates at density of 10^4 cells/well. Plates were centrifuged at 1,000 rpm for 10 min to facilitate clustering of the cells, as described by Chambers et al. [17]. Cells were then maintained them in the complete DMEM. Spheroids were treated with apigenin for 48 h. Phase-contrast images of them were taken using a Leica inverted microscope. Spheroid viability was determined by using an enhanced cell viability assay kit (CellVia, Seoul, Korea). Briefly, after adding 10 µl of Cellvia solution to each well, the plate was kept at room temperature for 1 h and then mixed by shaking for 1 min. Formazan formed by living cells was measured at wavelength of 450 nm using a GloMax-Multi Microplate Multimode Reader.

**Spheroid staining**

Cells were kept in the dark after adding FDA (5 µg/ml) and PI
RESULTS
DNA damage, transitional delay at G2/M phase, and cell death in apigenin-induced cytotoxicity

In MTT assay, when MSTO-211H and H-2452 cells were treated with increasing concentrations (0, 10, 30, and 50 μM) of apigenin for 48 h and 72 h, apigenin inhibited cell growth in a concentration and time-dependent manner (Fig. 1A). Although these cells were sensitive to apigenin treatment, MSTO-211H cells were more sensitive to such treatment than H-2452 cells. However, cisplatin treatment at the same concentration as apigenin showed low toxicity to MSTO-211H and H-2452 cells. In human normal mesothelial MeT-5A cells, apigenin showed cell viability of 90% or more at 48 h and 72 h treatment at 50 μM concentration. Cell cycle analysis of MM cells after apigenin treatment showed a concentration-dependent increase in the G2/M phase cell population along with a sub-G0/G1 peak suggesting cell death (Fig. 1B). The percentage of annexin V-PE positive cells increased to 21.1% for MSTO-211H cells treated with 30 μM apigenin compared
with 12.04% for H-2452 cells (Fig. 1C). To evaluate the effects of apigenin on DNA damage, we examined the phosphorylation levels of markers for DDR and DSB. As shown in Fig. 1D, apigenin increased the phosphorylation of ATM<sub>Ser1981</sub>, ATR<sup>Ser286</sup>, CHK1<sup>Ser345</sup>, and CHK2<sup>Thr68</sup> as well as histone H2A.X<sup>Ser139</sup>, a DSB marker, suggesting that apigenin could cause DSB and activate the ATM/ATR signaling pathway.

**Apigenin-induced cytotoxicity accompanies concurrent induction of apoptosis and necroptosis**

To elucidate mechanisms underlying cytotoxic effects of apigenin on MM cells, expression level of proteins involved in apoptosis and necroptosis were measured by Western blotting. As shown in Fig. 2A, apigenin increased levels of the cleaved forms of caspase-3 and its substrate PARP as well as an increase in the Bax/Bcl-2 ratio. Furthermore, apigenin increased expression levels of p-MLKL and p-RIP3 known to be necroptosis mediators. Inhibition of necroptosis or of apoptosis, either by pretreatment with necrostatin-1 or Q-VD-Oph-1, significantly enhanced cell viability at 48 h and 72 h treatment of apigenin (30 and 50 μM), suggesting that apigenin-induced cell death depended on apoptosis and necroptosis (Fig. 2B).

**ROS and ATP play critical roles in apigenin-induced cytotoxicity**

To investigate the role of intracellular ROS as upstream molecules of cytotoxicity induced by apigenin, DCF fluorescence assay was performed using flow cytometry. With increasing concentration of apigenin, the ROS level tended to gradually increase, but it showed a marked increase at 48 h of treatment (Fig. 3A), suggesting that apigenin-induced cytotoxicity might be in part due to excessive ROS. Next, we measured the ΔΨm to evaluate changes in the mitochondrial function after apigenin treatment. ΔΨm loss after apigenin treatment was higher in MSTO-211H cells compared to H-2452 cells (Fig. 3B). To evaluate the role of ATP in cytotoxicity that apigenin causes, changes in intracellular ATP level were measured in the apigenin-treated cells. In parallel with impaired mitochondrial function, ATP levels began to decrease within 2 h after apigenin treatment and was found to drop abruptly at 6 h (Fig. 3C). However, pretreatment with ROS scavenger N-acetylcysteine (NAC) restored ATP levels reduced by apigenin. ATP supplementation improved cell viability (Fig. 3D).

**Fig. 2. Apigenin-induced apoptosis and necroptosis in MSTO-211H and H-2452 cells.** (A) Cells were treated with increasing concentrations (0, 10, 30, and 50 μM) of apigenin for 48 h. Levels of apoptosis- and necroptosis-related proteins were assessed by Western blotting. (B) Cells were pretreated with 25 μM necrostatin-1 and 10 μM Q-VD-Oph-1 2 h prior to treatment with apigenin (30 and 50 μM) for 48 h and 72 h. Cell viability was measured by MTT assay. APG, apigenin. *p < 0.05 vs. respective control group. **p < 0.05 vs. group treated with APG alone.
and recovered DDR-, apoptosis-, and necroptosis-inducing molecules upregulated by apigenin to near-basal levels (Fig. 3E). These findings indicated that apigenin-induced cell death was caused by ATP depletion, at least in part.

Given the observation that excess ROS was linked to increased cytotoxicity, the effect of ROS scavenging on apigenin-treated cells was evaluated. Pretreatment of cells with NAC effectively restored ROS levels (Fig. 4A) and improved a series of effects induced by apigenin, including increased sub-G1/G0 peak and cell accumulation in G2/M phase of the cell cycle (Fig. 4B), increased annexin V-PE positive cell fractions (Fig. 4C), and an increased percentage of cells showing ΔΨm loss (Fig. 4D). In addition, pyknotic and fragmented nuclei observed in DAPI staining of apigenin-treated cells were not found in NAC treatment (Fig. 4E).

To determine whether the results of 2D cell culture matched those of 3D spheroid culture, spheroids derived from MSTO-211H and H-2452 cells were pre-incubated with or without NAC for 2 h, then treated with apigenin for an additional 48 h. Both viable and dead cells were visualized under a fluorescence microscope after having double stained them with FDA (green) and PI (red), respectively. As shown in Fig. 5A, apigenin increased red fluorescence in the necrotic core with green fluorescence on the spheroid surface. In parallel with the morphological findings, apigenin decreased cell viability in spheroids. However, this effect was blocked by NAC pretreatment (Fig. 5B). Cell viability after treatment with apigenin was slightly higher for 3D spheroid culture compared to that for 2D monolayer cell culture. Next, we investigated whether the expression of proteins related to apoptosis and necroptosis was affected by apigenin. As shown in Fig. 5C, levels of necroptosis-related proteins observed in the 3D spheroid

---

**Fig. 3. Effects of apigenin on mitochondrial function in MSTO-211H and H-2452 cells.** (A, B) Cells were treated with indicated concentrations of apigenin for 48 h. Intracellular ROS levels were measured after cells were stained with 10 μM DCF-DA (A). Mitochondrial membrane potential was measured after staining cells with 30 nM rhodamine123 (B). (C–E) Cells were pretreated with 5 mM NAC or 1 mM ATP for 2 h prior to treatment with 30 μM apigenin for 48 h. Cellular ATP levels were measured by CellTiter-Glo luminescent cell viability assay (C). Cell viability was measured by MTT assay (D). Levels of DNA damage response-, apoptosis-, and necroptosis-related proteins were assessed by Western blotting (E). APG, apigenin; NAC, N-acetylcysteine; ROS, reactive oxygen species. *p < 0.05 vs. respective control group. †p < 0.05 vs. group treated with APG alone.
Fig. 4. Apigenin-induced oxidative stress in MSTO-211H and H-2452 cells. Cells were pretreated with or without 5 mM NAC for 2 h prior to treatment with 30 μM apigenin for 48 h. (A) Cellular ROS levels were measured by staining cells with 10 μM DCF-DA. (B) Cell cycle distribution was determined by flow cytometry following staining with propidium iodide (20 μg/ml). (C) Apoptotic cell fraction was analyzed using annexin V-PE binding assay. (D) Δψm was measured by staining cells with 30 nM rhodamine123. APG, apigenin; NAC, N-acetylcysteine; Arrows, sub-G0/G1 peak.

Investigating the anti-cancer effects of apigenin on MM cells, we found the following changes in cellular response. First, apigenin treatment produced a significant cytotoxic effect, which was evidenced by an enhancement of DDR, a delayed transition at the G2/M phase in the cell cycle, and cell death. Second, the cell growth-inhibiting effect of apigenin was mediated by mitochondrial dysfunction through excessive ROS, MMP loss and ATP depletion. Third, increased cell death was caused by simultaneous induction of apoptosis and necroptosis. Fourth, compared to the results of 2D cell culture, the occurrence of necroptosis induced by apigenin was confirmed in 3D spheroid culture, although there was no change in the level of cleaved caspase-3.

Clinically, the side effects of chemotherapy are serious. They contribute to relapses and a poor prognosis after receiving chemotherapy. Taking this into consideration, we screened naturally occurring flavonoid compounds showing low toxic properties in normal mesothelial cell line MeT-5A with strong anti-cancer activity against MM cell lines MSTO-211H and H-2452, leading to the identification of apigenin which was subjected to further evaluation. In particular, cisplatin was much less toxic to MM cells at the same treatment concentration compared to apigenin. Extracellular acidification and release through exosomes are considered possible causes of cisplatin resistance [18].

Increased DDR and a transitional delay at G2/M phase of cell cycle analysis, observed in the present study, indicate activation of DNA repair pathways in response to DNA damage. DNA damage signaling can subsequently activate DNA damage check-
Apigenin-induced apoptosis has been reported to have effects on MM cells by increasing the activities of p53 and caspase-9 [20]. This effect has been associated with increased ROS production and DNA damage. In our data, induction of apoptosis by apigenin was caspase-dependent, consistent with previous report of Masuelli et al. [20] using in vivo and in vitro models. However, the necroptosis-inducing ability of apigenin through activation of the RIPK3/MLKL pathway has not been previously reported. Some evidence has suggested that targeting non-apoptotic cell death pathways might be an important strategy to develop new anti-cancer therapies since cancer cells can develop resistance to anti-cancer drugs by escaping apoptosis [21]. In this regard, activating necroptosis using agents like apigenin can be an alternative way to overcome anticancer drug resistance, thus killing cancer cells that cannot be killed by apoptosis. In addition, inhibiting both apoptosis and necroptosis after pretreatment of necroptosis inhibitor necrostatin-1 or apoptosis inhibitor Q-VD-Oph-1 has indicated that these two cell death modes are compatible to each other and that the common signals regulating them could be transmitted, although the exact mechanism remains elusive. Similar induction of apoptosis and necroptosis has been observed in ovarian cancer cells co-treated with berberine and cisplatin [22]. Caspase-8 and alternative splicing isoforms of FADD-like IL-1β-converting enzyme-inhibitory protein (cFLIP) such as cFLIPL and

---

**Fig. 5. Effects of pretreatment with N-acetylcysteine on apigenin-induced cytotoxicity in 3D cultures of MSTO-211H and H-2452 cells.** Spheroids were cultured in ultrawell cluster 96-well plate and pretreated with or without 5 mM NAC 2 h prior to treatment with 30 μM apigenin for 48 h. (A) Vitality staining of spheroids (from left to right: phase-contrast image [a], fluorescent images of FDA(+) living cells in green [b], PI(+) dead cells in red [c], and merged [d]) (×100). (B) Cell and spheroid viability were measured by MTT assay and the enhanced cell viability assay kit. (C) The levels of necroptosis- and apoptosis-related proteins were analyzed by Western blotting. APG, apigenin; NAC, N-acetylcysteine. *p < 0.05 vs. respective control group. 'p < 0.05 vs. group treated with APG alone.
Apigenin-induced necroptosis

ACKNOWLEDGEMENTS

This research was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea, funded by the Ministry of Education (No. NRF-2018R1D1A1B07046129).

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science. 1998;246:629-634.
2. Zannini L, Delia D, Buscemi G. CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol. 2014;6:442-457.
3. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1-13.
4. Higuchi Y. Glutathione depletion-induced chromosomal DNA fragmentation associated with apoptosis and necrosis. J Cell Mol Med. 2004;8:455-464.
5. Liu J, Wang Z. Increased oxidative stress as a selective anticancer therapy. Oxid Med Cell Longev. 2015;2015:294303.
6. Nagata Y, Sawada R, Takashima A, Shoji H, Honma Y, Iwasa S, Amano K, Kato K, Hamaguchi T, Shimada Y, Saruta M, Boku N. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. Jpn J Clin Oncol. 2019;49:1004-1008.
7. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol. 2004;5:354-362.
8. Galani V, Varouktsi A, Papadatos SS, Mitselou A, Sainis I, Constantinopoulos S, Dalavanga Y. The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment. Cancer Chemother Pharmacol. 2019;84:241-253.
9. Grootsjans S, Vanden Berghe T, Vandenabeele P. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ. 2017;24:1184-1195.
10. Chen D, Yu J, Zhang L. Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta. 2016;1865:228-236.
11. Diederich M, Cerella C. Non-canonical programmed cell death mechanisms triggered by natural compounds. Semin Cancer Biol. 2016;40-41:4-34.
12. Salehi B, Venditti A, Sharifi-Rad M, Kregiel D, Sharifi-Rad J, Durrazzo A, Lucarini M, Santini A, Souto EB, Novellino E, Antolak H, Azzini E, Setzer WN, Martins N. The therapeutic potential of apigenin. Int J Mol Sci. 2019;20:1305.
13. Yan X, Qi M, Li P, Zhan Y, Shao H. Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. Cell Biosci. 2017;7:50.
14. Shukla S, Gupta S. Apigenin: a promising molecule for cancer prevention. Pharm Rev. 2010;27:962-978.
15. Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12:207-218.
16. Nunes AS, Barros AS, Costa EC, Moreira AF, Correia I. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnol Bioeng. 2019;116:206-226.
17. Chambers KF, Mosaad EM, Russell PJ, Clements JA, Doran MR. 3D cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer. PLoS One. 2014;9:e11029.
18. Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, D’ilio S, Lugini L, Violante N, Azzarito T, Majorani C, Brambilla D, Fais S. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One.

www.kjpp.net

Korean J Physiol Pharmacol 2020;24(6):493-502
2014;9:e88193.

19. Giglia-Mari G, Zotter A, Vermeulen W. DNA damage response. *Cold Spring Harb Perspect Biol*. 2011;3:a000745.

20. Masuelli L, Benvenuto M, Mattera R, Di Stefano E, Zago E, Taffera G, Tresoldi I, Giganti MG, Frajese GV, Berardi G, Modesti A, Bei R. In vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma. *Front Pharmacol*. 2017;8:373.

21. Tait SW, Ichim G, Green DR. Die another way--non-apoptotic mechanisms of cell death. *J Cell Sci*. 2014;127(Pt 10):2135-2144.

22. Liu L, Fan J, Ai G, Liu J, Luo N, Li C, Cheng Z. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. *Biol Res*. 2019;52:37.

23. Tummers B, Green DR. Caspase-8: regulating life and death. *Immunol Rev*. 2017;277:76-89.

24. Safa AR. Roles of c-FLIP in apoptosis, necroptosis, and autophagy. *J Carcinog Mutagen*. 2013;Suppl 6:003.

25. Carlisi D, Buttiita G, Di Fiore R, Scerri C, Drago-Ferrante R, Vento R, Tesoriere G. Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction and necrosis. *Cell Death Dis*. 2016;7:e2194.

26. Chen S, Lv X, Hu B, Zhao L, Li S, Li Z, Qing X, Liu H, Xu J, Shao Z. Critical contribution of RIPK1 mediated mitochondrial dysfunction and oxidative stress to compression-induced rat nucleus pulposus cells necroptosis and apoptosis. *Apoloptosis*. 2018;23:299-313.

27. Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. *Cancer Res*. 1997;57:1835-1840.